International Consensus Statement on Rhinology and Allergy: Rhinosinusitis

Background: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods: ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results: ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion: This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS

The Correlation of Repeat Sprint Measures to Predicted VO2 in Recreationally Active College Age Males

1Miltenberger, M., 2Zipp, G., 2Lombardi, V., 2Parasher, R., 1Davis, S., 1East Stroudsburg University, East Stroudsburg, PA, 2Seton Hall University, South Orange, NJ Purpose: This study was designed to investigate the relationship between repeat sprint measures (peak sprint time, mean sprint time, fatigue index) and predicted VO2 (PVO2) calculated from the Queens College Step Test (QCT). Methods: Eighteen recreationally active male college students (Age 20.9 years ±1.5, Height 178.5cm ± 6.1, Mass 77.5 kg ± 9.8) volunteered to participate in this study. Each subject completed a repeat sprint protocol on an indoor track consisting of 12 x 30 meter sprints separated by 35 seconds of passive recovery. After a minimum of 48 hours subjects returned to complete a submaximal 3 minute step test consisting of 24 steps per minute. A 15 second recovery heart rate was recorded to determine PVO2. Relationships between sprint data (peak sprint time, mean sprint time, fatigue index) and PVO2 were established using Pearson Product Moment Correlations (SPSS version 20.0). Results: Statistical analysis revealed a significant negative relationship between mean sprint time and PVO2 (p=0.011, R= -0.586) suggesting that those subjects with higher aerobic ability or PVO2 would also have low mean sprint times. Correlations between peak sprint time and PVO2 as well as fatigue index and PVO2 failed to show statistical significance, p= 0.052 and p= 0.120 respectively. Conclusion: The findings of this study suggest that the QCT is a valid measure in the prediction of mean sprint ability. These results also provide further evidence to suggest that the aerobic energy system plays a key role in maintenance of performance across multiple sprint trials

A multicenter evaluation of a new EUS core biopsy needle: Experience in 200 patients.

Background and Objectives: We present a multicenter study of a new endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) needle (Acquire, Boston Scientific, Natick, MA). The aim of the study was to analyze the needle\u27s clinical performance when sampling solid lesions and to assess the safety of this device. Methods: We performed a multicenter retrospective study of patients undergoing EUS-FNB during July 1-November 15, 2016. Results: Two hundred patients (121 males and 79 females) underwent EUS-FNB of solid lesions with the Acquire needle. Lesions included solid pancreatic masses (n = 109), adenopathy (n = 45), submucosal lesions (n = 34), cholangiocarcinoma (n = 8), liver lesions (n = 6), and other (n = 8). Mean lesion size was 30.6 mm (range: 3-100 mm). The mean number of passes per target lesion was 3 (range: 1-7). Rapid onsite cytologic evaluation (ROSE) by a cytologist was performed in all cases. Tissue obtained by EUS-FNB was adequate for evaluation and diagnosis by ROSE in 197/200 cases (98.5%). Data regarding the presence or absence of a core of tissue obtained after EUS-FNB were available in 145/200 procedures. In 131/145 (90%) of cases, a core of tissue was obtained. Thirteen out of 200 patients (6.5%) underwent some form of repeat EUS-based tissue acquisition after EUS-FNB with the Acquire needle. There were no adverse events. Conclusion: Overall, this study showed a high rate of tissue adequacy and production of a tissue core with this device with no adverse events seen in 200 patients. Comparative studies of different FNB needles are warranted in the future to help identify which needle type and size is ideal in different clinical settings